The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. B, 1999, Pages 31-37

  Schedletzky, Holger ^a   Wiedemann, Bernd ^a   Heisig, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM MUTANT; DRUG RESISTANCE; ESCHERICHIA COLI; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; GENES, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 0032949901     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wang, J. C. (1991). DNA topoisomerases: why so many? Journal of Biological Chemistry 266, 6659-62.
2. Adams, D. E., Shekhtman, E. M., Zechiedrich, E. L., Schmid, M. B. & Cozzareli, N. R. (1992). The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 71, 277-88.
3. Peng, H. & Marians, K. J. (1993). Decatenation activity of topo-isomerase IV during oriC and pBR322 DNA replication in vitro. Proceedings of the National Academy of Sciences of the USA 90, 8571-5.
4. Kato, J., Suzuki, H. & lkeda, H. (1992). Purification and characterization of DNA topoisomerase IV in Escherichia coli. Journal of Biological Chemistry 267, 25676-84.
5. Shen, L. L. (1994). Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Advances in Pharmacology 29A, 285-304.
6. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
7. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A. et al. (1994). Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Molecular Microbiology 13, 641-53.
8. Hooper, D. C. & Wolfson, J. S. (1993). Mechanisms of bacterial resistance to quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 97-118. American Society for Microbiology, Washington, DC.
9. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
10. Heisig, P., Schedletzky, H. & Falkenstein-Paul, H. (1993). Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 669-701.
11. Heisig, P. & Tschorny, R. (1994). Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrobial Agents and Chemotherapy 38, 1284-91.
12. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
13. Bagel, S., Hüllen, V., Wiedemann, B. & Heisig, P. (1999). Impact of gyrA and parC mutations on quinolone resistance, doubling time and supercoiling degree of E. coli. Antimicrobial Agents and Chemotherapy 43, (In press).
14. Hamilton, C. M., Aldea, M., Washburn, B. K., Babitzke, P. & Kushner, S. R. (1989). New method for generating deletions and gene replacements in Escherichia coli. Journal of Bacteriology 171, 4617-22.
15. Takenouchi, T., Ishii, C., Sugawara, M., Tokue, Y. & Ohya, S. (1995). Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrobial Agents and Chemotherapy 39, 1414-8.
16. Heisig, P. (1993). High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. Journal of Antimicrobial Chemotherapy 32, 367-77.
17. Chapman, J. S. & Georgopapadakou, N. H. (1989). Fluorimetric assay for fleroxacin uptake by bacterial cells. Antimicrobial Agents and Chemothererapy 33, 27-9.
18. Kato, J., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S. & Suzuki H. (1990). New topoisomerase essential for chromosome segregation in E. coli. Cell 63, 393-404.
19. Mizuuchi, K., Mizuuchi, M., O'Dea, M. H. & Gellert, M. (1984). Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins. Journal of Biological Chemistry 259, 9199-201.
20. Tabor, S. & Richardson, C. C. (1985). A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proceedings of the National Academy of Sciences of the USA 82, 1974-8.
21. Staudenbauer, W. L. & Orr, E. (1981). DNA gyrase: affinity chromatography on novobiocin-sepharose and catalytic properties. Nucleic Acids Research 9, 3589-603.
22. Hoshino, K., Kitamura, A., Morrissey, I., Sato, K., Kato, J. & lkeda, H. (1994). Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy 38, 2623-7.
23. Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high level fluoroquinolone resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 879-85.
24. Kresken, M. & Hafner, D. (1996). Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Chemotherapie Journal 5, 225-30.